Free Trial
Janani Sundararajan

Janani Sundararajan Analyst Performance

Senior Research Associate at Chardan Capital

Janani Sundararajan is a stock analyst at Chardan Capital in the medical sector, covering 2 publicly traded companies. Over the past year, Janani Sundararajan has issued 8 stock ratings, including buy and hold recommendations. While full access to Janani Sundararajan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Janani Sundararajan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 0 Years
Buy Recommendations
71.43% 5 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy71.4%5 ratings
Hold28.6%2 ratings
Sell0.0%0 ratings

Out of 7 total stock ratings issued by Janani Sundararajan at Chardan Capital, the majority (71.4%) have been Buy recommendations, followed by 28.6% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
2 companies

Janani Sundararajan, an analyst at Chardan Capital, currently covers 2 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Janani Sundararajan of Chardan Capital specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
100.0%

About Janani Sundararajan

Dr. Janani Sundararajan is a Senior Research Associate at Chardan supporting Senior Analyst Keay Nakae in covering biotech companies, with a focus on microbiome and RNA therapeutics. Dr. Janani Sundararajan joined Chardan in the fall of 2021 as a Senior Research Associate covering Biotechnology. Prior to joining Chardan, Dr. Sundararajan was a Postdoctoral Research Fellow in the laboratory of Dr. Robert Froemke at New York University, where she studied the synaptic basis of auditory processing in the maternal brain. Dr. Sundararajan conducted her thesis research in the laboratory of Dr. Richard Mooney at Duke University, where she studied how movements affect auditory processing and perception. Dr. Sundararajan received her B.Eng from National University of Singapore, her PhD from Duke University, and was a Postdoctoral Research Fellow at New York University.
Follow on LinkedIn

Janani Sundararajan's Ratings History at Chardan Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Passage Bio, Inc. stock logo
PASG
Passage Bio
4/21/2026Set Price Target$6.25$7.00Neutral
Passage Bio, Inc. stock logo
PASG
Passage Bio
4/21/2026Downgrade$6.18$7.00Hold
Alumis Inc. stock logo
ALMS
Alumis
3/30/2026Reiterated Rating$24.80$38.00Buy
Alumis Inc. stock logo
ALMS
Alumis
3/20/2026Boost Price Target$25.38$38.00Buy
Alumis Inc. stock logo
ALMS
Alumis
1/21/2026Initiated Coverage$26.06$37.00Buy
Alumis Inc. stock logo
ALMS
Alumis
1/21/2026Initiated Coverage$26.06$37.00Buy
Alumis Inc. stock logo
ALMS
Alumis
1/21/2026Set Price Target$26.06$37.00
Alumis Inc. stock logo
ALMS
Alumis
1/21/2026Initiated Coverage$26.68$37.00Buy